Skip to content
10-Q

Quarterly Report

Vincerx Pharma, Inc.

0001193125-24-255248

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 33.56M sh
Shares Diluted Q3 2024 · Sep 30, 2024 45.67K sh
Shares Diluted Q3 2024 · Sep 30, 2024 35.18K sh
Shares Diluted Q3 2024 · Sep 30, 2023 21.35K sh
Shares Diluted Q3 2024 · Sep 30, 2023 21.27K sh
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$19.95M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$32.43M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.94M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $12.78M
Stockholders Equity Q3 2024 · Sep 30, 2024 $9.11M
Stockholders Equity Q3 2024 · Jun 30, 2024 $15.45M
Stockholders Equity Q3 2024 · Dec 31, 2023 $11.22M
Stockholders Equity Q3 2024 · Sep 30, 2023 $15.74M
Stockholders Equity Q3 2024 · Jun 30, 2023 $24.14M
Stockholders Equity Q3 2024 · Dec 31, 2022 $47.67M
Current Liabilities Q3 2024 · Sep 30, 2024 $5.42M
Current Liabilities Q3 2024 · Dec 31, 2023 $5.61M
Total Liabilities Q3 2024 · Sep 30, 2024 $5.84M
Total Liabilities Q3 2024 · Dec 31, 2023 $7M
Current Assets Q3 2024 · Sep 30, 2024 $11.75M
Current Assets Q3 2024 · Dec 31, 2023 $14.73M
Total Assets Q3 2024 · Sep 30, 2024 $14.95M
Total Assets Q3 2024 · Dec 31, 2023 $18.22M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.17
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.63
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.42
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.66
Eps Basic Q3 2024 · Sep 30, 2024 −$0.17
Eps Basic Q3 2024 · Sep 30, 2024 −$0.63
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.42
Eps Basic Q3 2024 · Sep 30, 2023 −$1.66
Sga Expense Q3 2024 · Sep 30, 2024 $3.89M
Sga Expense Q3 2024 · Sep 30, 2024 $10.42M
Sga Expense restated Q3 2024 · Sep 30, 2023 $3.51M
Sga Expense Q3 2024 · Sep 30, 2023 $11.82M
Net Income Q3 2024 · Sep 30, 2024 −$7.84M
Net Income Q3 2024 · Sep 30, 2024 −$22.08M
Net Income restated Q3 2024 · Sep 30, 2023 −$9.01M
Net Income Q3 2024 · Sep 30, 2023 −$35.21M
Operating Income Q3 2024 · Sep 30, 2024 −$7.79M
Operating Income Q3 2024 · Sep 30, 2024 −$22.64M
Operating Income restated Q3 2024 · Sep 30, 2023 −$9.61M
Operating Income Q3 2024 · Sep 30, 2023 −$37.08M